Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LSS | P48449 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30839665 | 1.00 | HRH3 (0.40) | HRH3KDM4EALDH1A1SMN1; SMN2LSS | |
| Boric Acid SCHEMBL28327201 | 0.79 | HRH3 (0.35) | HRH3KDM4EALDH1A1SMN1; SMN2LSS | |
| SCHEMBL21541768 | 0.77 | CXCR1 (0.39) | HRH3NOS3NOS1NOS2 | |
| SCHEMBL31090233 | 0.74 | KDM4E (0.62) | HRH3KDM4EALDH1A1SMN1; SMN2LSS | |
| SCHEMBL27815796 | 0.73 | TRPV1 (0.38) | — | |
| SCHEMBL15067149 | 0.71 | RXFP1 (0.52) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL7928336 | 0.69 | HRH3 (0.58) | HRH3KDM4EALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL15067284 | 0.69 | ATM (0.40) | KDM4EALDH1A1 | |
| SCHEMBL17841653 | 0.67 | CXCR2 (0.40) | HRH3CYP2D6 | |
| SCHEMBL29267535 | 0.67 | TRPV1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114026097-B | Substituted pyrazoloquinazolinone compounds and uses thereof | 上海瑛派药业有限公司 | 2024-02-23 | — | — | CN | disclosed |
| EP-3567041-B1 | SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2023-12-27 | — | — | EP | disclosed |
| CN-110167941-B | Substituted fused heteroaryl compounds as kinase inhibitors and uses thereof | 上海瑛派药业有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-3567041-A9 | SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-04-20 | — | — | EP | disclosed |
| US-10874670-B2 | Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2020-12-29 | — | — | US | disclosed |
| EP-3567041-A1 | SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF | Impact Therapeutics, Inc (CN) | 2019-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874670-B2 | Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof | CHEK1, CHEK2, CDK1 | HRH3 997/4885KDM4E 372/4885ALDH1A1 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.